On top of that, there's also a bonus The Last Attack post-credits scene, though that's mostly a joke non-canon sequence. In our opinion, The Last Attack is the definitive way to watch the final ...

J&J’s fading immunology star Stelara, meanwhile, suffered a setback in the quarter as biosimilars crept into the market. Another headwind was changes to the Medicare’s Part D policies. The drug pulled ...

Shields is referring to the large PBMs’ efforts to develop private-label biosimilars that compete directly with pharmaceutical companies’ biosimilars for Humira (adalimumab) and Stelara (ustekinumab).

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options ...

No significant differences in the risk of myocardial infarction, ischemic stroke, or cardiovascular-related death were observed in patients with psoriasis or psoriatic arthritis initiating treatment ...

Biological medicines, including biosimilar medicines, play an important role in healthcare, opening up many possibilities for the treatment of disease and illness. 8 of the top 10 medicines prescribed ...

The concerns around the Stelara exclusivity appear overblown. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the ...

They have also faced slow uptake as physicians and health systems struggle to adapt to the new treatment paradigm. Both Humira and Stelara work by tamping down the inflammatory response and share a ...

The actor chats with The Hollywood Reporter about why his character will fare better than the rest of the financially-ruined Ratliff family — and why he's shocked people have questions about ...

Federal prosecutors revealed that Ryan Routh, the accused would-be assassin of President Donald Trump, sought to obtain military-grade weapons – including a rocket launcher – from a Ukrainian ...

Johnson & Johnson also got a boost to Buy. Haider said concerns about losing patent protection on its blockbuster drug Stelara may be overstated. He pointed out that pharmaceutical valuations tend ...